During migration in tissue in vivo or in culture in a three-dimensional (3D) extracellular matrix (ECM), endothelial cells, fibroblasts and tumour cells exhibit a characteristic complex shape that ...

Myosin Marketing is hoping your desire to do some good in the world will supersede your annoyance at getting a random text. On Tuesday, Myosin, a self-described accelerator helping brands scale their ...

Living cells are highly organized, yet they are not assembled using rigid blueprints or by following a predetermined plan. Instead, order emerges on its own from countless interactions between ...

JUPITER, Fla., Feb. 26, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has closed its second seed funding ...

The novel cardiac myosin inhibitor aficamten improved peak oxygen uptake in symptomatic obstructive hypertrophic cardiomyopathy (HCM), the pivotal SEQUOIA-HCM trial showed. At 24 weeks, the mean ...

The team showed with microsecond resolution that the head of myosin first binds weakly to actin. That bond strengthens, however, as myosin moves along the actin filament and finds the position for ...

Each year, about 14,000 people in the United States are diagnosed with glioblastoma, one of the deadliest primary brain tumors. With standard treatments of surgery, radiation, and chemotherapy ...

In its early stages, Alzheimer disease is increasingly recognized as a disease of synapses, those key mediators of memory storage in the brain. Enhancing synaptic function, therefore, might be a ...

"This process appears to be regulated by myosin-binding protein-C (cMyBP-C), which is a heart muscle protein," study author Kerry McDonald said. "Our study investigated its role in cardiac muscle ...

Using technologies like electron microscopy (EM) it is possible to capture molecular mechanisms in great detail, but not when these mechanisms are currently moving. The field of cryomicroscopy ...

Secondary efficacy analyses of the pivotal SEQUOIA-HCM trial continued to favor aficamten, supporting a potential role for another cardiac myosin inhibitor in obstructive hypertrophic cardiomyopathy ...